Sculptra
Galderma
cheek wrinkles, nasolabial folds, marionette lines, chin wrinkles
Sculptra vs. Radiesse
Last verified 7/30/2026
Radiesse
Merz Aesthetics
nasolabial folds, lower face, jawline, dorsal hands
Quick comparison
| Attribute | Sculptra | Radiesse |
|---|---|---|
| Treatment category | Injectable | Injectable |
| What it targets | Gradual tissue support and correction of selected facial wrinkles or contour deficiencies. | Immediate volume and structural contour in approved tissue planes, with a subsequent tissue response. |
| How it works | PLLA microparticles produce a local tissue response associated with gradual collagen deposition; initial water-related fullness subsides before the treatment effect develops. | Calcium hydroxylapatite microspheres suspended in a gel carrier provide immediate fill; the carrier dissipates as tissue forms around the microspheres, which are gradually resorbed. |
| Common treatment areas | cheek wrinkles, nasolabial folds, marionette lines, chin wrinkles | nasolabial folds, lower face, jawline, dorsal hands |
| Whether it adds volume | Gradually, through biostimulation rather than a persistent HA gel bolus. | Yes, immediately |
| Results timing | Most clinical-study participants saw results by about one month; improvement develops gradually. | Immediate volume, followed by evolution as the carrier dissipates and tissue response develops. |
| Typical longevity | The current manufacturer summary and cheek clinical program report sustained improvement for up to two years; individual response varies. | FDA consumer guidance describes calcium hydroxylapatite filler effects as approximately 18 months; individual product, area, and patient results vary. |
| Reversibility | Not enzymatically reversible like an HA filler; effects and adverse nodules may be difficult to correct. | Not dissolvable with hyaluronidase; correction of unwanted placement can be difficult. |
| Downtime | Injection-site swelling, tenderness, redness, pain, bruising, bleeding, itching, and lumps can occur. | Swelling, bruising, redness, pain, itching, and tenderness can occur; hand and facial recovery differ. |
| Pricing basis | Usually per vial; compare the number of vials per session and the planned number of sessions. | Usually per 1.5 mL syringe; retain syringe volume, product version, area, and any dilution protocol. |
| Major risks | Injection reactions, papules or nodules including delayed inflammatory nodules, granuloma, infection, and intravascular injection with infarction or embolic phenomena. | Injection reactions, nodules, infection, material visibility or palpability, and rare intravascular injection with necrosis, visual loss, or stroke. |
| Primary limitations | Early post-injection fullness fades, results are gradual, and a multi-session course may be required. | Immediate correction can evolve as the carrier dissipates, and unwanted product cannot be simply enzymatically dissolved. |
Treatment category
- Sculptra
- Injectable
- Radiesse
- Injectable
What it targets
- Sculptra
- Gradual tissue support and correction of selected facial wrinkles or contour deficiencies.
- Radiesse
- Immediate volume and structural contour in approved tissue planes, with a subsequent tissue response.
How it works
- Sculptra
- PLLA microparticles produce a local tissue response associated with gradual collagen deposition; initial water-related fullness subsides before the treatment effect develops.
- Radiesse
- Calcium hydroxylapatite microspheres suspended in a gel carrier provide immediate fill; the carrier dissipates as tissue forms around the microspheres, which are gradually resorbed.
Common treatment areas
- Sculptra
- cheek wrinkles, nasolabial folds, marionette lines, chin wrinkles
- Radiesse
- nasolabial folds, lower face, jawline, dorsal hands
Whether it adds volume
- Sculptra
- Gradually, through biostimulation rather than a persistent HA gel bolus.
- Radiesse
- Yes, immediately
Results timing
- Sculptra
- Most clinical-study participants saw results by about one month; improvement develops gradually.
- Radiesse
- Immediate volume, followed by evolution as the carrier dissipates and tissue response develops.
Typical longevity
- Sculptra
- The current manufacturer summary and cheek clinical program report sustained improvement for up to two years; individual response varies.
- Radiesse
- FDA consumer guidance describes calcium hydroxylapatite filler effects as approximately 18 months; individual product, area, and patient results vary.
Reversibility
- Sculptra
- Not enzymatically reversible like an HA filler; effects and adverse nodules may be difficult to correct.
- Radiesse
- Not dissolvable with hyaluronidase; correction of unwanted placement can be difficult.
Downtime
- Sculptra
- Injection-site swelling, tenderness, redness, pain, bruising, bleeding, itching, and lumps can occur.
- Radiesse
- Swelling, bruising, redness, pain, itching, and tenderness can occur; hand and facial recovery differ.
Pricing basis
- Sculptra
- Usually per vial; compare the number of vials per session and the planned number of sessions.
- Radiesse
- Usually per 1.5 mL syringe; retain syringe volume, product version, area, and any dilution protocol.
Major risks
- Sculptra
- Injection reactions, papules or nodules including delayed inflammatory nodules, granuloma, infection, and intravascular injection with infarction or embolic phenomena.
- Radiesse
- Injection reactions, nodules, infection, material visibility or palpability, and rare intravascular injection with necrosis, visual loss, or stroke.
Primary limitations
- Sculptra
- Early post-injection fullness fades, results are gradual, and a multi-session course may be required.
- Radiesse
- Immediate correction can evolve as the carrier dissipates, and unwanted product cannot be simply enzymatically dissolved.
Benefits and trade-offs
Sculptra
- Gradual tissue support and correction of selected facial wrinkles or contour deficiencies.
- It does not provide the same predictable immediate gel contour as an HA filler and is not used in the lip vermilion or periorbital area under the IFU.
- Early post-injection fullness fades, results are gradual, and a multi-session course may be required.
Radiesse
- Immediate volume and structural contour in approved tissue planes, with a subsequent tissue response.
- It does not relax muscles and cannot be dissolved with hyaluronidase like an HA filler.
- Immediate correction can evolve as the carrier dissipates, and unwanted product cannot be simply enzymatically dissolved.
Details
Open a section for more context. Sources appear beside the claims they support.
Purpose and mechanism
| Attribute | Sculptra | Radiesse |
|---|---|---|
| How it works | PLLA microparticles produce a local tissue response associated with gradual collagen deposition; initial water-related fullness subsides before the treatment effect develops.
| Calcium hydroxylapatite microspheres suspended in a gel carrier provide immediate fill; the carrier dissipates as tissue forms around the microspheres, which are gradually resorbed.
|
| What it primarily changes | Gradual tissue support and correction of selected facial wrinkles or contour deficiencies.
| Immediate volume and structural contour in approved tissue planes, with a subsequent tissue response.
|
| What it does not change | It does not provide the same predictable immediate gel contour as an HA filler and is not used in the lip vermilion or periorbital area under the IFU.
| It does not relax muscles and cannot be dissolved with hyaluronidase like an HA filler.
|
| Adds volume | Gradually, through biostimulation rather than a persistent HA gel bolus.
| Yes, immediately
|
| Tightening effect | No device-like tightening; gradual collagen response may improve support.
| No device-like tightening; structural support and diluted off-label uses must not be conflated with labelled correction.
|
| Whether they are true substitutes | Sculptra and Radiesse both have biostimulatory effects but differ in material, immediate volume, reversibility, technique, and labelled uses.
| Overlaps with Sculptra in some broad goals but differs in immediate volume, composition, injection plan, reversibility, and labelled indications.
|
How it works
- Sculptra
- PLLA microparticles produce a local tissue response associated with gradual collagen deposition; initial water-related fullness subsides before the treatment effect develops.
- Sculptra Science · sculptrausa.com
- Radiesse
- Calcium hydroxylapatite microspheres suspended in a gel carrier provide immediate fill; the carrier dissipates as tissue forms around the microspheres, which are gradually resorbed.
- Radiesse (+) Instructions for Use · radiesse.com
What it primarily changes
- Sculptra
- Gradual tissue support and correction of selected facial wrinkles or contour deficiencies.
- Sculptra Aesthetic Instructions for Use · sculptrausa.com
- Radiesse
- Immediate volume and structural contour in approved tissue planes, with a subsequent tissue response.
- Radiesse (+) Instructions for Use · radiesse.com
What it does not change
- Sculptra
- It does not provide the same predictable immediate gel contour as an HA filler and is not used in the lip vermilion or periorbital area under the IFU.
- Sculptra Aesthetic Instructions for Use · sculptrausa.com
- Radiesse
- It does not relax muscles and cannot be dissolved with hyaluronidase like an HA filler.
- Radiesse (+) Instructions for Use · radiesse.com
Adds volume
- Sculptra
- Gradually, through biostimulation rather than a persistent HA gel bolus.
- Sculptra Aesthetic Instructions for Use · sculptrausa.com
Tightening effect
- Sculptra
- No device-like tightening; gradual collagen response may improve support.
- Sculptra Aesthetic Instructions for Use · sculptrausa.com
- Radiesse
- No device-like tightening; structural support and diluted off-label uses must not be conflated with labelled correction.
- Radiesse (+) Instructions for Use · radiesse.com
Whether they are true substitutes
- Sculptra
- Sculptra and Radiesse both have biostimulatory effects but differ in material, immediate volume, reversibility, technique, and labelled uses.
- Sculptra Aesthetic Instructions for Use · sculptrausa.com
- Radiesse
- Overlaps with Sculptra in some broad goals but differs in immediate volume, composition, injection plan, reversibility, and labelled indications.
- Radiesse (+) Instructions for Use · radiesse.com
Sessions, downtime and recovery
| Attribute | Sculptra | Radiesse |
|---|---|---|
| Typical number of sessions | Average 2 to 3 sessions over several months; typical treatment is three sessions at least 3 to 4 weeks apart.
| Often one treatment with individualized amount; additional treatment depends on area, response, and label.
|
| Downtime | Injection-site swelling, tenderness, redness, pain, bruising, bleeding, itching, and lumps can occur.
| Swelling, bruising, redness, pain, itching, and tenderness can occur; hand and facial recovery differ.
|
| Swelling | Common initially and can temporarily mimic correction before subsiding.
| Common after injection.
|
Typical number of sessions
- Sculptra
- Average 2 to 3 sessions over several months; typical treatment is three sessions at least 3 to 4 weeks apart.
- Sculptra Frequently Asked Questions · sculptrausa.com
- Radiesse
- Often one treatment with individualized amount; additional treatment depends on area, response, and label.
- Radiesse (+) Instructions for Use · radiesse.com
Downtime
- Sculptra
- Injection-site swelling, tenderness, redness, pain, bruising, bleeding, itching, and lumps can occur.
- Sculptra Aesthetic Instructions for Use · sculptrausa.com
- Radiesse
- Swelling, bruising, redness, pain, itching, and tenderness can occur; hand and facial recovery differ.
- Radiesse (+) Instructions for Use · radiesse.com
Swelling
- Sculptra
- Common initially and can temporarily mimic correction before subsiding.
- Sculptra Aesthetic Instructions for Use · sculptrausa.com
Longevity and reversibility
| Attribute | Sculptra | Radiesse |
|---|---|---|
| How long it lasts | The current manufacturer summary and cheek clinical program report sustained improvement for up to two years; individual response varies.
| FDA consumer guidance describes calcium hydroxylapatite filler effects as approximately 18 months; individual product, area, and patient results vary.
|
| Reversibility | Not enzymatically reversible like an HA filler; effects and adverse nodules may be difficult to correct.
| Not dissolvable with hyaluronidase; correction of unwanted placement can be difficult.
|
How long it lasts
- Sculptra
- The current manufacturer summary and cheek clinical program report sustained improvement for up to two years; individual response varies.
- FDA Summary of Safety and Effectiveness Data P030050/S039 · accessdata.fda.gov
- Radiesse
- FDA consumer guidance describes calcium hydroxylapatite filler effects as approximately 18 months; individual product, area, and patient results vary.
- FDA-Approved Dermal Fillers · fda.gov
Reversibility
- Sculptra
- Not enzymatically reversible like an HA filler; effects and adverse nodules may be difficult to correct.
- Sculptra Aesthetic Instructions for Use · sculptrausa.com
- Radiesse
- Not dissolvable with hyaluronidase; correction of unwanted placement can be difficult.
- Radiesse (+) Instructions for Use · radiesse.com
Risks and limitations
| Attribute | Sculptra | Radiesse |
|---|---|---|
| Documented risks | Injection reactions, papules or nodules including delayed inflammatory nodules, granuloma, infection, and intravascular injection with infarction or embolic phenomena.
| Injection reactions, nodules, infection, material visibility or palpability, and rare intravascular injection with necrosis, visual loss, or stroke.
|
| Most likely disappointment | Early post-injection fullness fades, results are gradual, and a multi-session course may be required.
| Immediate correction can evolve as the carrier dissipates, and unwanted product cannot be simply enzymatically dissolved.
|
| When this treatment may not be appropriate | Contraindicated with ingredient hypersensitivity or a history of keloid formation or hypertrophic scarring; not for lip vermilion or periorbital injection under the IFU.
| When a reversible HA option is required, the desired area is not in the product labelling, or product contraindications or active infection apply.
|
| Provider-dependent variables | Reconstitution, hydration time, dilution, injection plane, distribution, session spacing, massage instruction, and avoiding overcorrection.
| Product version, dilution if any, plane, area, amount, anatomy, and complication management.
|
Documented risks
- Sculptra
- Injection reactions, papules or nodules including delayed inflammatory nodules, granuloma, infection, and intravascular injection with infarction or embolic phenomena.
- Sculptra Aesthetic Instructions for Use · sculptrausa.com
- Radiesse
- Injection reactions, nodules, infection, material visibility or palpability, and rare intravascular injection with necrosis, visual loss, or stroke.
- Radiesse (+) Instructions for Use · radiesse.com
Most likely disappointment
- Sculptra
- Early post-injection fullness fades, results are gradual, and a multi-session course may be required.
- Sculptra Aesthetic Instructions for Use · sculptrausa.com
- Radiesse
- Immediate correction can evolve as the carrier dissipates, and unwanted product cannot be simply enzymatically dissolved.
- Radiesse (+) Instructions for Use · radiesse.com
When this treatment may not be appropriate
- Sculptra
- Contraindicated with ingredient hypersensitivity or a history of keloid formation or hypertrophic scarring; not for lip vermilion or periorbital injection under the IFU.
- Sculptra Aesthetic Instructions for Use · sculptrausa.com
- Radiesse
- When a reversible HA option is required, the desired area is not in the product labelling, or product contraindications or active infection apply.
- Radiesse (+) Instructions for Use · radiesse.com
Provider-dependent variables
- Sculptra
- Reconstitution, hydration time, dilution, injection plane, distribution, session spacing, massage instruction, and avoiding overcorrection.
- Sculptra Aesthetic Instructions for Use · sculptrausa.com
- Radiesse
- Product version, dilution if any, plane, area, amount, anatomy, and complication management.
- Radiesse (+) Instructions for Use · radiesse.com
Evidence and regulatory status
| Attribute | Sculptra | Radiesse |
|---|---|---|
| United States regulatory status | FDA-approved by PMA and supplements for specified facial contour deficiencies and wrinkles, including the 2023 cheek fine-line and wrinkle indication.
| FDA-approved by PMA and supplements for product-specific facial and hand indications; current Radiesse (+) labelling must be checked for the exact area.
|
| Canadian regulatory status | Health Canada MDALL lists Sculptra under active Class III licence 71658.
| Health Canada MDALL lists active Class III licences for Radiesse (78893) and Radiesse (+) (95140).
|
| Evidence status | High for indication, treatment course, safety, and two-year cheek-study follow-up; aesthetic response and vial needs vary.
| High for composition, approved-use framework, immediate filler action, and serious risks; off-label dilution outcomes are not generalized.
|
United States regulatory status
- Sculptra
- FDA-approved by PMA and supplements for specified facial contour deficiencies and wrinkles, including the 2023 cheek fine-line and wrinkle indication.
- SCULPTRA summary of safety and effectiveness · accessdata.fda.gov
- FDA PMA P030050/S039 · accessdata.fda.gov
- Radiesse
- FDA-approved by PMA and supplements for product-specific facial and hand indications; current Radiesse (+) labelling must be checked for the exact area.
- RADIESSE summary of safety and effectiveness · accessdata.fda.gov
- FDA PMA database: Radiesse P050052 · accessdata.fda.gov
Canadian regulatory status
- Sculptra
- Health Canada MDALL lists Sculptra under active Class III licence 71658.
- Health Canada MDALL: Q-Med licences · health-products.canada.ca
- Radiesse
- Health Canada MDALL lists active Class III licences for Radiesse (78893) and Radiesse (+) (95140).
- Health Canada MDALL: Merz Radiesse licences · health-products.canada.ca
Evidence status
- Sculptra
- High for indication, treatment course, safety, and two-year cheek-study follow-up; aesthetic response and vial needs vary.
- FDA PMA P030050/S039 · accessdata.fda.gov
- Radiesse
- High for composition, approved-use framework, immediate filler action, and serious risks; off-label dilution outcomes are not generalized.
- FDA PMA database: Radiesse P050052 · accessdata.fda.gov
SourcesShowHide
Sources are grouped by treatment so the support for each record stays visible.
Sculptra
- FDA PMA P030050/S039 · accessdata.fda.gov, 2023-04-04 · supports 2 fields
- FDA Summary of Safety and Effectiveness Data P030050/S039 · accessdata.fda.gov, 2023-04-04
- Health Canada MDALL: Q-Med licences · health-products.canada.ca
- Sculptra Aesthetic Instructions for Use · sculptrausa.com, 2023-04-01 · supports 20 fields
- Sculptra Frequently Asked Questions · sculptrausa.com
- Sculptra Science · sculptrausa.com
- SCULPTRA summary of safety and effectiveness · accessdata.fda.gov
Radiesse
- FDA PMA database: Radiesse P050052 · accessdata.fda.gov · supports 2 fields
- FDA-Approved Dermal Fillers · fda.gov
- Health Canada MDALL: Merz Radiesse licences · health-products.canada.ca
- Radiesse (+) Instructions for Use · radiesse.com, 2024-04-01 · supports 22 fields
- RADIESSE summary of safety and effectiveness · accessdata.fda.gov
See average treatment prices near you
Enter a US ZIP code or Canadian postal code to check our stored estimate for the surrounding market.